Patents by Inventor Franklin Gerardus Grosveld
Franklin Gerardus Grosveld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11877565Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: GrantFiled: July 23, 2015Date of Patent: January 23, 2024Assignee: ERASMUS UNIVERSITY MEDICAL CENTERInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen
-
Publication number: 20220275059Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.Type: ApplicationFiled: February 20, 2020Publication date: September 1, 2022Inventors: Franklin Gerardus GROSVELD, Marinus Johannes VAN HAPEREN, Dubravka DRABEK, Berend Jan BOSCH, Ivy WIDJAJA, Chunyan WANG, Brenda VAN DIEREN, Wentao LI, Frank J.M. VAN KUPPEVELD, Bart L. HAAGMANS, Nisreen M.A. OKBA
-
Publication number: 20220017606Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. in some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection, In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).Type: ApplicationFiled: July 20, 2021Publication date: January 20, 2022Inventors: Franklin Gerardus Grosveld, Dubravka Drabek, Rien Van Haperen, Berend Jan Bosch, Juliette Fedry, Daniel L. Hurdiss, Thijs Kuiken, Batholomeus Leonardus Haagmans, Barry Hubertus Gerardus Rockx
-
Publication number: 20210340225Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).Type: ApplicationFiled: March 5, 2021Publication date: November 4, 2021Inventors: Franklin Gerardus Grosveld, Dubravka Drabek, Rien van Haperen, Berend Jan Bosch, Juliette Fedry, Daniel L. Hurdiss, Thijs Kuiken, Batholomeus Leonardus Haagmans, Barry Hubertus Gerardus Rockx
-
Patent number: 10993420Abstract: A transgenic non-human mammal containing a heterologous heavy chain gene locus that is capable of producing soluble heavy chain only antibodies and antigen-binding fragments thereof following immunization.Type: GrantFiled: March 14, 2014Date of Patent: May 4, 2021Assignee: ERASMUS UNIVERSITY MEDICAL CENTERInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens
-
Patent number: 10906970Abstract: The present invention relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge.Type: GrantFiled: April 16, 2018Date of Patent: February 2, 2021Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Publication number: 20200267951Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.Type: ApplicationFiled: April 15, 2020Publication date: August 27, 2020Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Roger Kingdon Craig
-
Patent number: 10638735Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.Type: GrantFiled: December 8, 2015Date of Patent: May 5, 2020Assignee: Erasmus University Medical CenterInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Roger Kingdon Craig
-
Publication number: 20180244765Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: ApplicationFiled: April 16, 2018Publication date: August 30, 2018Applicant: ERASMUS UNIVERSITY MEDICAL CENTRE ROTTERDAMInventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Patent number: 9980470Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: GrantFiled: March 14, 2014Date of Patent: May 29, 2018Assignee: Erasmus University Medical CenterInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen, Roger Kingdon Craig, Ernie De Boer
-
Publication number: 20160295843Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.Type: ApplicationFiled: December 8, 2015Publication date: October 13, 2016Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Roger Kingdon Craig
-
Publication number: 20160295842Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: ApplicationFiled: July 23, 2015Publication date: October 13, 2016Applicant: Erasmus University Medical CenterInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen
-
Patent number: 9365655Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.Type: GrantFiled: March 15, 2013Date of Patent: June 14, 2016Assignee: Erasmus University Medical CenterInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer
-
Patent number: 9353179Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: GrantFiled: March 15, 2013Date of Patent: May 31, 2016Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Patent number: 9346877Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: GrantFiled: March 15, 2013Date of Patent: May 24, 2016Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Patent number: 9131669Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: GrantFiled: March 14, 2013Date of Patent: September 15, 2015Assignee: ERASMUS UNIVERSITY MEDICAL CENTERInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen
-
Patent number: 8921522Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: GrantFiled: December 23, 2009Date of Patent: December 30, 2014Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Publication number: 20140356908Abstract: A transgenic non-human mammal containing a heterologous heavy chain gene locus that is capable of producing soluble heavy chain only antibodies and antigen-binding fragments thereof following immunization.Type: ApplicationFiled: March 14, 2014Publication date: December 4, 2014Applicant: ERASMUS UNIVERSITY MEDICAL CENTERInventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS
-
Publication number: 20140356907Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: ApplicationFiled: March 14, 2014Publication date: December 4, 2014Applicant: ERASMUS UNIVERSITY MEDICAL CENTERInventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS, MARINUS JOHANNES VAN HAPEREN, ROGER KINGDON CRAIG, ERNIE DE BOER
-
Patent number: 8883150Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.Type: GrantFiled: March 19, 2010Date of Patent: November 11, 2014Assignee: Erasmus University Medical CenterInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer